AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
AMARIN CORP PLC\UK (AMRN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $567.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-03-02
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $567.00K.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $0.00.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $113.00K.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $155.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $567.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-12 |
| 2023-12-31 | $113.00K 10-K · filed 2024-02-29 |
| 2022-12-31 | $155.00K 10-K · filed 2023-03-01 |
| 2021-12-31 | $7.76M 10-K · filed 2022-03-01 |
| 2020-12-31 | $23.12M 10-K · filed 2021-02-25 |
| 2019-12-31 | $231.90M 10-K · filed 2020-02-25 |
| 2018-12-31 | $184.90M 10-K · filed 2019-02-27 |
| 2017-12-31 | $34.02M 10-K · filed 2018-02-27 |
| 2016-12-31 | $16.40M 10-K · filed 2017-03-01 |
| 2015-12-31 | $520.00K 10-K · filed 2016-02-25 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-03 |
| 2013-12-31 | $1.06M 10-K · filed 2014-02-27 |
| 2012-12-31 | $25.93M 10-K · filed 2013-02-28 |
| 2011-12-31 | $40.25M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |